一种新的分类与回归树算法:利用钆塞酸二钠增强MRI提高≤3.0 cm肝细胞癌的诊断敏感度
本研究基于分类与回归树(CART)分析和LI-RADS特征,开发并验证了用于钆塞酸二钠增强MRI诊断≤3.0 cm肝细胞癌的算法。在开发队列(299例)和验证队列(90例)中,该算法诊断明确肝细胞癌的总体敏感度(开发队列93.2%,验证队列92.5%)显著高于Jiang算法改良LR-5和LI-RADS LR-5,特异度相当(开发队列84.3%,验证队列86.7%),平衡准确度最高(开发队列91.2%,验证队列91.6%)。
要点
- 新CART算法纳入靶样表现、肝胆期低信号、非环状动脉期高强化、移行期低信号伴轻中度T2高信号。
- 诊断≤3.0 cm肝细胞癌的敏感度:开发队列93.2%,验证队列92.5%,显著高于对照算法。
- 特异度与LI-RADS LR-5相当(开发队列84.3%,验证队列86.7%),平衡准确度最高达91.6%。
核心结论
- 在高危患者中,基于LI-RADS特征开发的CART算法在钆塞酸二钠增强MRI上对≤3.0 cm肝细胞癌的早期诊断显示出应用前景。
研究设计与样本
- 回顾性纳入2018年1月至2021年2月两家机构接受钆塞酸二钠增强MRI的高危患者,机构1为开发队列(299例),机构2为验证队列(90例),以病理或临床标准为参考。
关键影像表现/征象
- 靶样表现、肝胆期低信号、非环状动脉期高强化、移行期低信号伴轻中度T2高信号是算法纳入的影像特征。
- 算法以决策树形式呈现,用于鉴别肝细胞癌与非肝细胞癌病变。
诊断标准与关键数值
- 新CART算法诊断明确肝细胞癌的敏感度:开发队列93.2%,验证队列92.5%(P < 0.006)。
- 新CART算法特异度:开发队列84.3%,验证队列86.7%(P ≥ 0.006),与Jiang算法改良LR-5和LI-RADS LR-5相当。
- 新CART算法平衡准确度:开发队列91.2%,验证队列91.6%,高于其他标准。
- Jiang算法改良LR-5定义为靶样表现、非周边廓清、弥散受限和非环状动脉期高强化。
临床应用与阅片要点
- 对于≤3.0 cm的肝脏病变,可参考本算法纳入的LI-RADS特征(靶样表现、肝胆期低信号、非环状动脉期高强化、移行期低信号伴轻中度T2高信号)进行结构化评估。
- 本算法在保持与LI-RADS LR-5相当特异度的同时提高了敏感度,可能有助于早期检出小肝细胞癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop and validate an effective algorithm, based on classification and regression tree (CART) analysis and LI-RADS features, for diagnosing HCC ≤ 3.0 cm with gadoxetate disodium‑enhanced MRI (Gd-EOB-MRI).
METHOD: We retrospectively included 299 and 90 high-risk patients with hepatic lesions ≤ 3.0 cm that underwent Gd-EOB-MRI from January 2018 to February 2021 in institution 1 (development cohort) and institution 2 (validation cohort), respectively. Through binary and multivariate regression analyses of LI-RADS features in the development cohort, we developed an algorithm using CART analysis, which comprised the targeted appearance and independently significant imaging features. On per-lesion basis, we compared the diagnostic performances of our algorithm, two previously reported CART algorithms, and LI-RADS LR-5 in development and validation cohorts.
RESULTS: Our CART algorithm, presenting as a decision tree, included targetoid appearance, HBP hypointensity, nonrim arterial phase hyperenhancement (APHE), and transitional phase hypointensity plus mild-moderate T2 hyperintensity. For definite HCC diagnosis, the overall sensitivity of our algorithm (development cohort 93.2%, validation cohort 92.5%; P < 0.006) was significantly higher than those of Jiang's algorithm modified LR-5 (defined as targetoid appearance, nonperipheral washout, restricted diffusion, and nonrim APHE) and LI-RADS LR-5, with the comparable specificity (development cohort: 84.3%, validation cohort: 86.7%; P ≥ 0.006). Our algorithm, providing the highest balanced accuracy (development cohort: 91.2%, validation cohort: 91.6%), outperformed other criteria for identifying HCCs from non-HCC lesions.
CONCLUSIONS: In high-risk patients, our CART algorithm developed with LI-RADS features showed promise for the early diagnosis of HCC ≤ 3.0 cm with Gd-EOB-MRI.
引用
- Pan J, Ye S, Song M, et al. A new classification and regression tree algorithm: Improved diagnostic sensitivity for HCC ≤ 3.0 cm using gadoxetate disodium-enhanced MRI. Eur J Radiol. 2023. PMID: 36933495. doi:10.1016/j.ejrad.2023.110770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。